Skip to main content

Table 2 Clinicopathologic characteristics with respect to ERα protein and ESR1 mRNA expression in the p16+/HPV+ OPSCC group

From: Estrogen receptor α as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma

CharacteristicsERα protein (n = 79)ESR1 mRNA (n = 71)
PositiveNegativep valuePositiveNegativep value
Sex
 Male33 (91.7%)36 (83.7%)0.33215 (100%)48 (85.7%)0.189
 Female3 (8.3%)7 (16.3%) 08 (14.3%) 
Age (years)
 < 6525 (69.4%)30 (69.8%)112 (80%)37 (66.1%)0.363
 ≥ 6511 (30.6%)13 (30.2%) 3 (20%)19 (33.9%) 
Smoking history
 Never13 (36.1%)17 (39.5%)0.8183 (20%)22 (39.3%)0.228
 Ever23 (63.9%)26 (60.5%) 12 (80%)34 (60.7%) 
Subsite
 Palatine tonsil31 (86.1%)37 (86%)0.58913 (86.6%)47 (83.9%)0.886
 Base of tongue4 (11.1%)3 (7%) 1 (6.7%)6 (10.7%) 
 Pharyngeal wall1 (2.8%)3 (7%) 1 (6.7%)3 (5.4%) 
Sample type
 Biopsy specimen13 (36.1%)12 (27.9%)0.4747 (46.7%)15 (25%)0.12
 Resected specimen23 (63.9%)31 (72.1%) 8 (53.3%)42 (75%) 
Surgical margina
 Clear19 (82.6%)20 (64.5%)0.2556 (75%)30 (71.4%)1
 Involved4 (17.4%)11 (35.5%) 2 (25%)12 (28.6%) 
Lymphovascular invasiona
 Absent14 (60.9%)16 (51.6%)0.5885 (62.5%)21 (50%)0.704
 Present9 (39.1%)15 (48.4%) 3 (37.5%)21 (50%) 
Perineural invasiona
 Absent22 (95.7%)28 (90.3%)0.5638 (100%)38 (90.5%)1
 Present1 (4.3%)3 (9.7%) 04 (9.5%) 
Initial stage (8th AJCC)
 I22 (61.1%)24 (55.8%)0.0627 (46.7%)34 (60.7%)0.125
 II14 (38.9%)13 (30.2%) 8 (53.3%)16 (28.6%) 
 III06 (14%) 06 (10.7%) 
HPV type
 Type 1625 (69.4%)39 (90.7%)0.022*11 (73.3%)46 (82.1%)0.475
 Type other than 1611 (30.6%)4 (9.3%) 4 (26.7%)10 (17.9%) 
Total36 (45.6%)43 (54.4%) 15 (21.1%)56 (78.9%) 
  1. ERα estrogen receptor α, ESR1 estrogen receptor 1, HPV human papillomavirus, AJCC American Joint Committee on Cancer
  2. *p < 0.05
  3. aEvaluated only in 54 and 50 surgical resection specimens for ERα and ESR1, respectively
\